DrugPatentWatch Database Preview

Details for Patent: 8,182,838

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,182,838 protect, and when does it expire?

Patent 8,182,838 protects SEEBRI and UTIBRON and is included in two NDAs.

This patent has sixty-three patent family members in twenty-three countries.

Summary for Patent: 8,182,838

Title:	Dry powder composition comprising co-jet milled particles for pulmonary inhalation
Abstract:	The present invention relates to particles and to methods of making particles. In particular, the invention relates to methods of making composite active particles comprising a pharmaceutically active material for pulmonary inhalation, the method comprising a jet milling process.
Inventor(s):	Morton; David (Chippenham, GB), Staniforth; John (Chippenham, GB)
Assignee:	Vectura Limited (Chippenham, GB)
Application Number:	10/571,146
Patent Claim Types: see list of patent claims	Use; Composition; Delivery;

Drugs Protected by US Patent 8,182,838

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	SEEBRI	glycopyrrolate	POWDER;INHALATION	207923-001	Oct 29, 2015		DISCN	Yes	No			Y
Novartis	UTIBRON	glycopyrrolate; indacaterol maleate	POWDER;INHALATION	207930-001	Oct 29, 2015		DISCN	Yes	No			Y

Foreign Priority and PCT Information for Patent: 8,182,838

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0321607.4	Sep 15, 2003

PCT Information
PCT Filed	September 15, 2004	PCT Application Number:	PCT/GB2004/003996
PCT Publication Date:	March 24, 2005	PCT Publication Number:	WO2005/025536

International Family Members for US Patent 8,182,838

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	535233
Australia	2004228757
Australia	2004231342
Australia	2004271779
Australia	2004271783
Brazil	PI0409380
Brazil	PI0414428